Piramal Pharma Share Price Live

History

Piramal Pharma Limited was established as a public limited company on March 4, 2020, and has developed a diverse portfolio of products and services. The company boasts an extensive global presence with manufacturing capabilities in 17 facilities worldwide and a distribution network spanning over 100 countries. Its business operations encompass an integrated Contract Development and Manufacturing Organisation (CDMO), Consumer Healthcare Goods (CHG) business, and over-the-counter (OTC) product sales in India.

Piramal Pharma Limited has also formed a significant joint venture with Allergan (now part of AbbVie), a leading name in ophthalmology, focusing on the Indian formulations market. This venture, named Allergan India Private Limited, sees Piramal Pharma holding a 49% stake in the paid-up equity share capital. The company also has a 33.33% minority investment in Yapan Bio, active in the biologics, bio-therapeutics, and vaccine segments.

Piramal Pharma Limited’s expansion included acquiring the pharmaceutical business from Piramal Enterprises Limited (PEL) in June 2020 and a growth equity investment from the Carlyle Group in October 2020. It also fully acquired Convergence Chemicals Private Limited (CCPL) and announced significant expansions in the UK and USA facilities. In 2021, it took over Hemmo Pharmaceuticals Private Limited (HPPL), specialising in peptide API development and manufacturing.

A notable development in 2021 was the Composite Scheme of Arrangement, effective from August 18, 2022, involving the demerger of the Pharma Business from PEL to Piramal Pharma Limited, the amalgamation of CCPL and HPPL into Piramal Pharma, and the amalgamation of PHL Fininvest Private Limited into PEL. As a result of the demerger, PEL’s equity shareholders received four Piramal Pharma shares for each share held in PEL, leading to the company’s listing on the BSE and NSE on October 19, 2022.

In 2022, Piramal Pharma further expanded by acquiring a minority stake in Yapan Bio Private Limited, a CDMO specialising in biologics and vaccines. The company also launched 26 new products and 37 new SKUs during the fiscal year 2023, demonstrating its commitment to growth and innovation in the pharmaceutical industry.

Business Segments 

Piramal Pharma operates under three main business segments, each catering to a distinct area of the pharmaceutical industry:

1. Contract Development and Manufacturing Organisation (CDMO): This segment offers end-to-end development and manufacturing services for innovators and generic companies across the drug life cycle. PPS boasts a global network of facilities spanning continents, offering expertise in complex dosage forms, potent APIs, and biologics.
2. Complex Hospital Generics: This segment focuses on high-barrier-to-entry, niche, and life-saving injectable medications primarily administered in hospitals. PCC’s portfolio includes inhalation anaesthetics, intrathecal therapies, injectable pain medications, and anti-infectives. They hold leading positions in several key markets globally.
3. OTC Products: This segment markets and distributes established over-the-counter (OTC) brands in India across various categories like baby care, skin care, women’s health, allergy management, gastrointestinal, vitamins and minerals, and analgesics. Popular brands include Little’s, Lacto Calamine, I-Pill, and Polycrol.

Subsidiaries of Piramal Pharma Limited

Piramal Pharma Limited has 20 subsidiaries overseas as of March 31, 2023. Some of them are:

• Piramal Healthcare UK Limited: This subsidiary, based in the United Kingdom, operates in the healthcare sector and is likely involved in pharmaceutical manufacturing, research, or distribution.
• Piramal Healthcare (Canada) Limited: Located in Canada, this subsidiary is engaged in pharmaceutical and healthcare-related activities, including manufacturing, research, or distribution of pharmaceutical products in Canada.
• Piramal Critical Care Inc: This subsidiary focuses on critical care and medical products. It specialises in producing and distributing critical care pharmaceuticals and medical devices to support patient care during critical and emergency situations. The specific location may vary based on its operational base.

Key Personnel 

Ajay Piramal, Chairman 

Ajay Piramal is the Chairman of the Piramal Group, a global conglomerate interested in pharmaceuticals, financial services, and real estate. The group operates in 30 countries and markets its products in over 100 markets. Mr. Piramal is known for his commitment to responsible entrepreneurship and the philosophy of ‘Doing Well and Doing Good.’ He emphasises trusteeship and social entrepreneurship, actively leading the Piramal Foundation’s initiatives to address socio-economic challenges in India. The foundation has impacted over 112 million lives in partnership with state governments and NITI Aayog across healthcare, nutrition, and education in 25 Aspirational Districts across 7 states.

Corporate Actions

Rights 

Piramal Pharma Limited announced rights issuance with a ratio of 5:46 at a premium of ₹71 per share. The rights issue had a record date of August 2, 2023.